MaxCyte launches new generation of cellular engineering instruments

MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.

The medicines and life sciences company said the newly introduced products introduce updated software, a touch-screen user interface and other features that deliver a significant improvement to the user experience and will enable customers to standardize on a single, unifying technology from early research through to clinical and commercial use.

Brad Calvin, executive vice president of global commercial operations for MaxCyte, said: "The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies. Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies."

The AIM traded company said the new products build on a foundation of its solid technology and its past instrument platforms, which are used by all of the top ten biopharmaceutical companies by revenue.

Doug Doerfler, president and chief executive of MaxCyte, said: "We are proud to announce the launch of our next-generation ExPERT brand of instruments. We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases."

MaxCyte's shares were down 0.27% at 187.00p at 1143 BST.